Cancer Research The Future of Cancer Research: Science and Patient Impact Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Research 66, 11520-11539, December 15, 2006. doi: 10.1158/0008-5472.CAN-06-2848
© 2006 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Horsman, M. R.
Right arrow Articles by Siemann, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horsman, M. R.
Right arrow Articles by Siemann, D. W.
Related Collections
Right arrow Therapeutics and Targets
Right arrow Therapeutics and Targets: Experimental Therapeutics– Biologics
Right arrow Clinical Research: Clinical Trials

Reviews

Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies

Michael R. Horsman1 and Dietmar W. Siemann2

1 Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark and 2 Department of Radiation Oncology, University of Florida, Gainesville, Florida

Requests for reprints: Michael R. Horsman, Department of Experimental Clinical Oncology, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark. Phone: 45-89492622; Fax: 45-86197109; E-mail: mike{at}oncology.dk.


   Abstract
Top
 Abstract
Introduction
 Vascular-Targeting Approaches
 Pathophysiologic Effects of VTAs
 Combining VTAs with Other...
 Summary and Conclusions
 References
 
A functional vascular supply is critical for the continued growth and development of solid tumors. It also plays a major role in metastatic spread of tumor cells. This importance has led to the concept of targeting the vasculature of the tumor as a form of cancer therapy. Two major types of vascular-targeting agent (VTA) have now emerged: those that prevent the angiogenic development of the neovasculature of the tumor and those that specifically damage the already established tumor vascular supply. When used alone neither approach readily leads to tumor control, and so, for VTAs to be most successful in the clinic they will need to be combined with more conventional therapies. However, by affecting the tumor vascular supply, these VTAs should induce pathophysiologic changes in variables, such as blood flow, pH, and oxygenation. Such changes could have negative or positive influences on the tumor response to more conventional therapies. This review aims to discuss the pathophysiologic changes induced by VTAs and the implications of these effects on the potential use of VTAs in combined modality therapy. (Cancer Res 2006; 66(24): 11520-39)


   Introduction
Top
 Abstract
 Introduction
Vascular-Targeting Approaches
 Pathophysiologic Effects of VTAs
 Combining VTAs with Other...
 Summary and Conclusions
 References
 
The development of a functional blood supply is essential to most solid tumors (1, 2). Typically, tumors can only grow to a few millimeters in size before the tumor cells begin to exist beyond the diffusion distance of oxygen and other essential nutrients. Further growth and development of the tumor then requires the formation of a vascular system to meet the demands of the growing tumor mass. The neovasculature that arises does so from the normal host vessels by the process of angiogenesis (3, 4) and not only provides tumor cells with oxygen and nutrients necessary for survival but is also the principal vehicle for metastatic spread (5). Furthermore, the tumor vascular supply influences the microenvironmental conditions within tumors and as such has a significant effect on the tumor response to therapy (6, 7). The importance of the tumor neovasculature thus makes it a potential therapeutic target.

Targeting the tumor vascular supply for cancer therapy is not a new concept. Indeed, the deliberate use of bacterial infections in cancer treatment in the 1800s involved an effect that was at least partially mediated through vascular targeting (8). Furthermore, as early as the 1920s, the concept of specifically targeting tumor vasculature as a potential therapy was proposed (9). However, it is only more recently that the use of vascular-targeting agents (VTA) has become established as a viable possibility (10, 11). Two major approaches have now emerged. One is based on controlling the blood vessel development by inhibiting the angiogenesis process [angiogenesis-inhibiting agents (AIA)], and the other involves compromising the function of the already existing blood vessels [vascular-disrupting agents (VDA)]. It is now becoming increasingly clear that vascular effects are involved in the action of other therapies, including certain types of chemotherapy, radiotherapy, and inhibitors of epidermal growth factor receptor or cyclooxygenase-2 (12–14), but because the vasculature is not the principal target of these other therapies, they will not be discussed in this review. Instead, we will restrict our comments to those therapies that are specifically designed to target tumor endothelium with little direct effect on the neoplastic cell population.

Regardless of the VTA approach used, it is unlikely that any VTA on its own will lead to tumor control, and the clinical potential of such agents will most likely be realized when combined with more conventional therapies. However, the tumor vascular supply can play a critical role in determining tumor response to such conventional treatments. The tumor blood supply will influence the delivery of blood-borne agents, including chemotherapeutic drugs, antibodies, and gene therapy approaches. It also controls the tumor microenvironment, and this is known to influence tumor response to drugs, radiation, and heat. Because VTAs affect tumor vascularity, they most likely will induce pathophysiologic changes that can have both a negative or a positive influence on the therapy with which it is combined. The aim of this review is to summarize the pathophysiologic changes caused by VTAs and discuss the implications of these changes when using VTAs in a combined modality setting.


   Vascular-Targeting Approaches
Top
 Abstract
 Introduction
 Vascular-Targeting Approaches
Pathophysiologic Effects of VTAs
 Combining VTAs with Other...
 Summary and Conclusions
 References
 
Although AIAs and VDAs both target the tumor vascular supply, they are two distinct approaches (15). AIAs are designed to prevent further development of the tumor neovascular network. Numerous agents capable of inhibiting new blood vessel formation have been identified, and each affects at least one of the several important stages of angiogenesis. The primary targets are the angiogenic factors, which play the most significant role in neovascularization (16). These are secreted by the tumor cells and are up-regulated by various environmental factors, such as hypoxia, loss of tumor suppressor gene function, and oncogene activation (16, 17). Of these angiogenic factors, the most potent and specific is vascular endothelial growth factor (VEGF), which not only is crucial for endothelial cell proliferation and blood vessel formation but also induces significant vascular permeability and plays a key role in endothelial cell survival signaling in newly formed vessels (16, 17). VEGF has been targeted by a variety of strategies (18–21), including monoclonal antibodies [e.g., bevacizumab (Avastin) and DC101], inhibitors of endothelial cell receptor-associated tyrosine kinase activity (e.g., SU5474, SU6668, ZD6474, and PTK787/ZK 222584), and antisense. Other approaches, including those targeting basement membrane degradation, endothelial cell migration, endothelial cell proliferation, and tube formation, have also been actively considered (18–21). Many of these antiangiogenic therapies are currently under clinical evaluation (18, 20, 22).

VDAs are agents that cause direct damage to the already established tumor endothelium (10, 23–26). These include physical treatments, such as hyperthermia or photodynamic therapy (PDT), which have been well documented to induce direct tumor cell killing and an indirect effect through the induction of vascular damage (10, 23). They also include biological response modifiers or cytokines, such as tumor necrosis factor (TNF) and interleukins; certain established chemotherapeutic drugs, such as Vinca alkaloids and arsenic trioxide (ATO); and various ligand-based approaches that use antibodies, peptides, or growth factors that can selectively bind to tumor vessels (10, 23–26). But more commonly, VDAs involve the use of small-molecule drugs (26), of which there are two major classes of agents. The first includes flavone acetic acid (FAA) and its derivative 5,6-dimethylxanthenone-4-acetic acid (DMXAA), which have a complex mechanism of action that is poorly understood, but their main effect on vascular endothelial cells is thought to involve a cascade of direct and indirect effects, the latter involving the induction of cytokines, especially TNF-{alpha}, leading to the induction of hemorrhagic necrosis (27, 28). A second group includes the tubulin-binding agents combretastatin A-4 disodium phosphate (CA4P), the phosphate prodrug of N-acetyl-colchinol (ZD6126), AVE8062, NPI2358, MN-029, and OXi4503 (26, 28). These tubulin-depolymerizing agents are primarily believed to selectively disrupt the cytoskeleton of proliferating endothelial cells, resulting in endothelial cell shape changes and subsequent thrombus formation and vascular collapse (28). Because they preferentially target dividing endothelial cells, this accounts for their tumor specificity. Both types of small molecular drugs have been shown to have potent antivascular and antitumor efficacy in a wide variety of preclinical models, and the lead agents are undergoing clinical evaluation (24).

Because AIAs and VDAs induce vascular effects by very different mechanisms, their antitumor activity and optimal application will be very different. Figure 1 illustrates the major differences. Generally, AIAs are given as a chronic administration and essentially slow tumor development (26). There are examples where tumor growth can be completely inhibited or the treatment of established tumors can result in tumor regression, but these tend to be exceptions rather than the norm (29–31). Consequently, AIAs are probably best suited for early-stage or metastatic disease. With VDAs, the administration is of a more acute type to induce substantial vascular shutdown (26). Antitumor effects should also be possible with lower doses given over a prolonged period, but that would probably increase the risk of normal tissue vessel damage and defeat the potential benefit. Following treatment with VDAs, tumor shrinkage has been observed, but this seems to be tumor and drug dependent and although significant it is generally modest and thus tumor growth is only temporarily delayed (26, 32). There is good evidence that VDAs have a superior effect on bulky disease (33–35). Also illustrated in Fig. 1 is the effect one observes when AIAs and VDAs are combined. In terms of antitumor activity, the inhibition of tumor growth with the combination is greater than the effects from either treatment alone, and this has been shown with several different combinations of AIAs and VDAs (36–41). Still, irrespective of whether the VTAs are given alone or in combination, for tumor control to be obtained these agents typically must be combined with more conventional therapies.


Figure 1
View larger version (41K):
[in this window]
[in a new window]

  		Figure 1. Schematic representation of the effects of AIAs and VDAs on tumors. Gray, tumors; red, normal and neovasculature; blue, induced necrosis. Tumor growth only occurs after they have established their own functional blood supply by angiogenesis. This growth can be inhibited using either AIAs (Figure 1) or VDAs (Figure 1), alone or in combination, given under optimal conditions. Inset, actual growth data for the human ovarian carcinoma OW1 grown s.c. on the flanks of nude mice and treated when at 200 mm3 in size. Animals were treated with vehicle control ({circ}), ZD6474 given p.o. on days 1 to 5 at a dose of 25 mg/kg (bullet), ZD6126 injected i.p. on days 1, 3, and 5 at a dose of 100 mg/kg ({triangleup}), or a combination of both ZD6474 and ZD6126 ({blacktriangleup}). Results are mean values for eight mice per group and are taken from ref. 36.

 

   Pathophysiologic Effects of VTAs
Top
 Abstract
 Introduction
 Vascular-Targeting Approaches
 Pathophysiologic Effects of VTAs
Combining VTAs with Other...
 Summary and Conclusions
 References
 
Angiogenesis inhibitors. When compared with the normal tissue vessels from which it arises, the tumor vascular supply is very different (6, 7). It is very primitive in nature, morphologically and functionally abnormal, and typically unable to keep pace with the rapidly growing tumor cell mass. Consequently, the neovascular network fails to meet the demands of the tumor cells for oxygen and nutrients, and this failure results in the development of oxygen-deficient, nutrient-deprived, and highly acidic conditions within the tumor (6, 7). Surprisingly, clonogenic cells can survive in such adverse environmental conditions and are known to play a major role in influencing tumor response to therapy (42, 43) and malignant progression (44, 45).

The inhibition of tumor growth induced by treatment with AIAs is generally associated with a reduced vascular density. This has been shown for anti-VEGF monoclonal antibodies (46, 47), tyrosine kinase inhibitors (29, 31, 47–49), and nonspecific inhibitors, such as endostatin (50, 51), arginine deiminase (47), and anginex (52). However, it is not a universal finding and there are examples where vascular density remained unchanged (52–55) and even one example where it increased (56) despite tumor growth being inhibited. In those situations where vascular density is reduced, it would be expected to increase the adverse microenvironmental conditions within the tumor. Indeed, as listed in Table 1 , studies with several different AIAs have reported a decrease in tumor oxygenation status, measured using a variety of conventional end points, such as the Eppendorf polarographic oxygen electrode (47, 52), hypoxic markers (57), or classic radiation response assays (58, 59). Two studies did not measure tumor oxygenation directly but found a decrease in tumor blood perfusion (60, 61), and such changes would have been expected to decrease tumor oxygenation as was seen with anginex (52). However, a reduced oxygenation status with AIA treatment is clearly not a universal phenomenon. Some studies reported no change in tumor oxygenation (46, 47, 49, 55, 62). Using endostatin in a well-vascularized MCa35 mammary carcinoma, this lack of effect was not surprising because the AIA also had no apparent influence on tumor vasculature or growth (55). But for the anti-VEGF monoclonal antibodies in the LS1747 colon adenocarcinoma (46) and 54A small cell lung cancer (62), tumor growth inhibition was reported, and in the LS1747 tumor, this was associated with a decrease in the number of tumor vessels (46). Furthermore, with arginine deiminase, the lack of any effect on oxygenation status of the WAC2 neuroblastoma was observed, despite the AIA decreasing tumor vascular density and perfusion and inhibiting tumor growth (47).


View this table:
[in this window]
[in a new window]

  		Table 1. Effect of AIAs on tumor oxygenation status

 
AIA-induced improvements in tumor oxygenation have also been reported (46, 50, 55, 56, 63–67). In one study using the anti-VEGF monoclonal antibody DC101 in a Shionogi mammary carcinoma grown in a window chamber, it was shown that, as untreated tumors grew, vascular density increased whereas oxygenation status decreased (50). Treatment with DC101 every 3 days for a total of 18 days resulted in a general decrease in vascular density and corresponding decrease in oxygenation. It was only at the end of the treatment period that vascular density and oxygenation began to increase. Interestingly, tumor oxygen consumption was unchanged in control tumors and remained relatively constant throughout the initial period of treatment with DC101, only increasing toward the end of treatment. Tumor oxygenation was also increased by an anti-VEGF monoclonal antibody in U87 glioblastomas (46). However, no change was observed when using a clamped tumor growth delay assay, leading to the authors questioning the significance of the oxygenation changes. Similar results were also reported for thrombospondin in a D-12 human melanoma using tumor growth delay (64), but a clear reduction in hypoxia was seen using the classic paired survival curve assay, suggesting that AIAs can decrease tumor hypoxia but that they have other effects that can sometimes mask the improvements in tumor oxygenation. One study that clearly showed an improvement in oxygenation status during treatment with an AIA was that of Winkler et al. (65). Using the hypoxic cell marker pimonidazole, they found a significant improvement in oxygenation of a human glioblastoma xenograft grown orthotopically in the mouse brain during treatment with DC101. This improvement corresponded to a transient period of stabilization of the tumor vessels, in which less mature vessels are destroyed and other vessels are stabilized by the recruitment of pericytes. This stabilization period has been termed the "normalization window" (68). Interestingly, additional studies with the angiogenic inhibitor thalidomide and measuring oxygenation in murine FSaII fibrosarcomas and TLT liver tumors using electron paramagnetic resonance oximetry reported a similar transient window of improved oxygenation (66, 67). The apparent transient nature of this effect would suggest that unless the timing of oxygenation measurement is optimal then the improvement in oxygenation by AIAs could be missed and this could account for the lack of effect in five of the studies in Table 1. But it certainly does not account for those studies showing a decrease in oxygenation. Moreover, the study by Winkler et al. (65) showed that, 2 days after treating animals with DC101 (3 x 40 mg/kg), tumors were still significantly better oxygenated, yet in the study by Fenton et al. (57), using the same DC101 drug and a similar schedule (3 x 45 mg/kg), the tumors 2 days after treatment were significantly more hypoxic. These findings suggest that the normalization effect may not be universally observed or, at the very least, a tumor-dependent phenomenon.

Another major pathophysiologic effect of AIAs that has often been reported involves changes in interstitial fluid pressure (IFP). In general, tumor IFP is high, although it is normally lower at the tumor periphery (69, 70). Following treatment with AIAs, IFP drops (46, 66, 71, 72). With vascular density decreasing then, the most likely explanation for a decrease in IFP would be a decrease in the number of tumor cells, and indeed, there is evidence that treatment with AIAs can lead to tumor cell killing (47, 73). However, other mechanisms may also be involved. One study with PTK787/ZK 222584, a specific inhibitor of the VEGF receptor tyrosine kinases, showed using dynamic contrast-enhanced magnetic resonance imaging in a murine renal cell carcinoma that this inhibitor could decrease vessel permeability and such an effect would be expected to reduce IFP (48).

Vascular-disrupting agents. The effects of VDAs on tumor pathophysiology are less controversial. As a consequence of inducing vascular damage, blood perfusion is reduced, and this has been reported for TNF (74, 75), Vinca alkaloids (76–78), ATO (79, 80), FAA (76, 81, 82), DMXAA (83–85), CA4P (84–87), ZD6126 (88–90), AVE8062 (91, 92), OXi4503 (93–96), and MN-029 (97). This is illustrated in Fig. 2 using examples from the two major classes of small-molecule drugs, in which perfusion in one tumor model was measured using the RbCl uptake technique. Typically, the reductions in tumor perfusion occur rapidly, often being detected within minutes after administering the VDA and achieving maximal shutdown within 1 to 6 hours (79–87, 89–91, 93–97). The actual degree and duration of the vascular shutdown are dependent on drug type, drug dose, and tumor model. For example, in a KHT sarcoma, a CA4P dose of 100 mg/kg will produce a >80% maximal decrease in perfusion (85, 98) that shows only a partial recovery at 24 hours (85), but in a C3H mammary carcinoma, this same dose only produces a 25% decrease and maximal reductions are only observed when the drug dose is increased to 250 mg/kg (98), and at both doses perfusion fully recovers by 24 hours (84). With DMXAA, a 20 mg/kg dose will produce a maximal >70% decrease in perfusion in both the KHT sarcoma (85) and C3H mammary carcinoma (99), and this reduction is maintained in both models for at least 24 hours after treatment (85, 99). These differences may reflect different mechanisms by which the VDAs induce vascular effects. How each VDA produces the effect is not clear, but two basic mechanisms have been proposed (28). The first involves a direct effect on endothelial cells, which induces effects, such as rounding up, blebbing, and apoptosis, all of which can lead to vessel blockage (28, 100, 101). Such changes have been detected in vitro but are more difficult to show in vivo (102). Alternatively, there is a more indirect effect mediated through an increase in vessel permeability, which may still be endothelial cell related. Increases in vessel permeability have been shown both in vivo and even clinically (103–109) and should decrease blood viscosity and increase IFP; the former will decrease flow and thus clotting is more likely, whereas the latter will increase the likelihood of vessel collapse. Actual measurements of IFP, primarily made using the wick-in-needle technique, generally show a decrease in IFP after treatment with VDAs (91, 110, 111). These decreases are time and drug dose dependent and begin to occur rapidly after drug injection; for CA4P in a C3H mouse mammary carcinoma3 and its analogue AVE8062 in a LY80 rat tumor model (91), such decreases were seen within 15 minutes. Interestingly, these changes in IFP occurred either at the same time (91) or actually followed (111)3 rather than preceded the VDA-induced decrease in tumor blood perfusion. One study actually reported no effect of CA4P on IFP in a BT4An rat tumor model and an increase with vinblastine (112). However, those measurements were made 3 hours after treatment and the study with ZD6126 in KHT sarcomas showed a decrease in IFP at 1 hour after injection, but at 3 hours, IFP had returned or even exceeded pretreatment levels followed by a progressive decrease reaching ~25% of control values by 72 hours after treatment (111), again confirming the importance of timing. Recently, Vincent et al. (113) showed the selective disruption of the molecular engagement of the endothelial cell junction protein vascular endothelial-cadherin following VDA treatment, providing another possible factor involved in tumor vessel disruption by this class of agents. Regardless of the mechanism(s), the ultimate effect of the vascular shutdown is ischemia and cell death, reflected by an increase in tumor necrosis. This has been observed with ATO (79, 105), FAA (114), DMXAA (83, 99), CA4P (86, 98, 115, 116), ZD6126 (88, 90, 102), OXi4503 (94, 96), and MN-029 (97). The effect of some of these VDAs on necrosis in a C3H mammary carcinoma is also illustrated in Fig. 2 and shows that even within one tumor model the effects of VDAs can be highly variable, an effect that is probably related to the severity of the vascular collapse.


Figure 2
View larger version (48K):
[in this window]
[in a new window]

  		Figure 2. Pathophysiologic effects of treating a C3H mouse mammary carcinoma with VDAs. Tumors were grown in the right rear foot of female CDF1 mice and treated when at 200 mm3 in size. Animals were given either no treatment (controls) or a single i.p. injection of FAA (150 mg/kg), DMXAA (20 mg/kg), CA4P (250 mg/kg), or ZD6126 (200 mg/kg). Results show relative changes in perfusion (RbCl uptake; percentage injected/gram tumor), necrotic fraction (percentage determined from histologic analysis), hypoxia (percent pO2 values < 5 mmHg as measured with an Eppendorf electrode), or tumor pH (estimated from 31P MRS measurements). Measurements of perfusion, hypoxia, and pH were made either 1 hour (CA4P and ZD6126) or 3 hours (FAA and DMXAA) after injection. Necrotic fraction was determined after 24 hours after giving all VDAs. Columns, mean (n = 6–8); bars, SE. Taken from refs. 81, 90, 98, 99, 125 and unpublished observations. n.d., not done.

 
The VDA-induced reductions in functional tumor vasculature will also be reflected in changes in other pathophysiologic variables, and some of these are illustrated in Fig. 2. Most solid animal and human tumors contain varying degrees of hypoxia (6, 117). Following treatment with VDAs, tumor oxygenation status decreases even further (78, 118–122). This is clearly associated with the increased necrosis, but studies using 19F magnetic resonance imaging oximetry suggest that there is a decrease in oxygenation status even in viable tissue (122). Recent measurements of blood flow changes in the tissue that survives VDA treatment support this notion.4 Tumor pH is another pathophysiologic factor affected by VDAs. The consensus opinion is that intracellular pH of tumor cells is generally maintained within the range typically found in normal cells, whereas extracellular pH tends to be acidic (6, 123). Treatment with VDAs results in a significant and rapid decrease in extracellular pH (124). However, VDAs can also decrease intracellular pH (125–127), and this latter effect is also illustrated in Fig. 2.


   Combining VTAs with Other Therapies
Top
 Abstract
 Introduction
 Vascular-Targeting Approaches
 Pathophysiologic Effects of VTAs
 Combining VTAs with Other...
Summary and Conclusions
 References
 
Radiation therapy. Combining AIAs with radiation is a logical step. Tumor progression is a major reason for radiotherapy failure and so by inhibiting such progression one should be able to improve radiation response. Numerous preclinical studies have investigated the potential of combining AIAs and radiation, and these studies are summarized in Table 2 . The radiation treatments have involved both single and fractionated schedules. For single radiation treatments, there are clear differences in the total doses given, whereas in the fractionated studies, not only do the total doses vary considerably, there are also large differences both in the number of fractions given and the time over which the doses were delivered. The AIAs evaluated include both nonspecific as well as targeted molecules. Here, the lack of standardization is even more obvious. This is true not only for the drug doses and treatment times used but also for the different combination schedules applied with radiation. These include administering the inhibitor during the radiation treatment (54, 59, 66, 128–135), before starting the irradiation (46, 51, 53, 58, 60), after completing the radiation (47, 72, 136), or a combination of before, during, and/or after irradiation (49, 52, 57, 61, 62, 64, 65, 72, 73, 128, 129, 135, 137–143). Such differences make broad generalizations very difficult. However, there is one aspect on which all but a few agree and that is that the combination of AIA and radiation is superior to either treatment alone. Several studies even suggest that this combination gives a result that is greater than an additive response. But without detailed analysis (144, 145), such conclusions may be extremely tenuous. Still, even an additive outcome would have a major benefit provided similar enhancements are not observed in critical normal tissues. Although additional data are clearly needed, one study that did investigate this issue (Table 2; ref. 62) reported no change in radiation-induced skin damage by DC101.


View this table:
[in this window]
[in a new window]

  		Table 2. Preclinical tumor studies combining AIAs with radiation

 
The response of any cell type to radiation is strongly dependent on oxygen concentration (146, 147), and because AIAs have been shown to improve the oxygenation status of tumors (46, 50, 55, 56, 63–67), the potential for a greater than additive effect when AIAs and radiation are combined clearly exists. However, those studies that have investigated the time dependency of this AIA-induced improvement in tumor oxygenation reported that the window of opportunity to exploit this possibility was short (65–67). Indeed, when combined with radiation, the only time synergy was observed was when the radiation was administered at the time of maximal reduction in tumor hypoxia (65). Irradiating immediately before, or after, this period only resulted in an additive response to the AIA and radiation treatment, although hypoxia was still significantly reduced at these times. This suggests that changes in oxygenation may not be the only factor involved, and unless it is possible to accurately predict the window of opportunity for each drug and tumor type, the potential for exploiting oxygenation modification by AIAs remains minimal. At the same time, there is clear evidence that AIAs can also induce hypoxia in tumors (47, 52, 57–61), and such an effect has the potential to reduce the efficacy of the radiation treatment, a result that has also been reported (58, 59). Such a negative effect is a major concern when trying to translate the preclinical studies into clinical trials, and to avoid such a potential problem, it would seem prudent to administer AIAs after radiation.

Several studies have actually investigated the importance of sequencing between radiation and AIAs especially with tyrosine kinase inhibitors. One study using A451 tumors gave a single radiation treatment, either 1 day before or 1 day after the start of a 3-week treatment with SU11657, and found that the latter schedule was superior (72). An additional study using ZD6474 in a fractionated drug and radiation treatment schedule over a 2-week period showed that the combination effect was additive and independent of whether the drug was given before (neoadjuvant), during (concomitant), or after (adjuvant) the radiation treatment (141). Similarly, the same drug given concurrently with radiation in another tumor model was only additive, but when an adjuvant schedule was used, a larger enhancement was obtained (61). An adjuvant schedule was also found to be superior to neoadjuvant or concomitant administration of PTK787/ZK 222584 and radiation in head and neck tumors (140). This benefit of the adjuvant schedule was suggested to be a consequence of the "tumor bed effect" (136). This is a well-known phenomenon in which tumor growth can be delayed by implanting tumors into an area that had been previously treated with high-dose radiation (148, 149). Zips et al. (150) later showed that the growth of FaDu tumors, which were normally unresponsive to a daily dose of 50 mg/kg PTK787/ZK 222584, could be inhibited by this treatment when tumors were grown in a preirradiated bed. They suggested that tumors vascularized by radiation-damaged vessels were far more sensitive to AIA treatment. More recent studies indicate that tumor endothelial cells may be an important target for radiation damage (13) and this could lead to a potential "target interaction" for AIAs and radiation. Indeed, it has been shown in vivo that the decrease in microvessel density (MVD) seen after treatment with AIAs can be further enhanced when radiation is also administered (49, 72, 130, 131, 137, 138). Additional in vitro studies using various types of cultured endothelial cells confirm a direct interaction between AIAs and radiation (54, 72, 130, 131, 134, 137, 138), an effect that may be mediated through an increase in apoptosis (72, 138). Probably, the most significant finding from these in vitro studies was that, when AIAs and radiation were combined, an enhanced response was seen regardless of whether a neoadjuvant (54, 72, 134, 137, 138), concomitant (138, 151), or adjuvant (130, 133, 142) schedule was used. Interestingly, the administration of VEGF could actually rescue human umbilical vascular endothelial cells from the radiation-mediated cell death (133, 151). This interaction between AIA and radiation was sometimes seen in tumor cells (72, 142), but not in all cases (130, 137), suggesting an endothelial cell–specific effect that could be exploited.

Treating tumors with VDAs produces an effect, which even when severe is typically restricted to the central part of the tumor, leaving a rim of viable tumor cells at the periphery (83, 86, 89, 115, 152). This is presumably because the tumor rim receives its nutritional support from nearby normal tissue blood vessels, which are generally unaffected by the VDA treatment (34, 153). Those tumor cells surviving in the periphery are also probably better oxygenated than the more central ones and as such would be expected to be more sensitive to radiation therapy. This suggests a logical rationale for combining VDAs with radiation. Such a combination has been the focus of numerous preclinical studies, and these are summarized in Table 3 . All these studies have been done in rodent tumor models and involved both single-dose radiation/drug treatments as well as fractionated schedules. Several studies investigated the importance of timing and sequence between the VDA and radiation treatment (89, 98, 154, 155). By far, the greatest antitumor activity was observed when the VDA was administered within a few hours after irradiating. With such a schedule, there was an indication that the effect was greater than a simple additive response to each agent alone, suggesting some sort of interaction between the two treatments rather than the VDA and radiation killing two different cell populations. Precisely how the VDAs and radiation might interact is not clear. Recent studies suggest that tumor vasculature may also be an important target for radiation damage (13), and it is possible that some form of interaction at the level of the endothelial cells is occurring, perhaps through the VDA increasing the extent of radiation-induced apoptosis as has been shown in vitro with TNF and radiation (156).


View this table:
[in this window]
[in a new window]

  		Table 3. Preclinical tumor studies combining VDAs with radiation

 
It has also been shown that injecting mice with the VDA and then irradiating typically has little or no benefit, and in some situations, there was an indication that the combined effect was less than an additive response to each agent alone (89, 98, 154, 155). This suggested that the vascular shutdown induced by the VDA may have rendered some tumor cells hypoxic at the time of irradiation and that those same cells later reoxygenated and survived. Further support for this concept comes from studies in which the combined effect of DMXAA and radiation could be enhanced by including the hypoxia-selective bioreductive drug tirapazamine in the treatment schedule (154). The reduced effect obtained when giving the VDA before radiation has important clinical applications in which fractionated radiation schedules are generally used. To avoid any possible complications, the optimal approach would probably involve giving the VDA after the last radiation treatment each week in a conventional fractionated schedule. Using such an approach, several preclinical studies have shown a benefit of combining VDAs and fractionated radiation (89, 153, 157, 158). Giving the VDA more often could still be beneficial provided there is sufficient time for any induced hypoxia to disappear before the next radiation treatment is applied. Indeed, one study using DMXAA and radiation showed that VDAs could be administered more often than once a week during a fractionated schedule without loss of benefit (154). However, whether this holds true for all VDAs and tumor types is not known, and this critical issue of hypoxia induction by VDAs and the possible consequences of such an induction clearly need further investigation.

Improving tumor response to therapy by combining VDAs and radiation will only be of benefit if such a combination does not enhance the response of critical normal tissues to the same degree. This is an aspect that has not been investigated in great detail. However, the preclinical results that have been obtained from the limited studies that have been done are encouraging. Using normal tissues that show an early response to radiation damage, such as skin (98, 154, 155), or late responding bladder and lung (159), no enhancement of radiation damage was observed. This is perhaps not entirely surprising because, although VDAs can induce some vascular shutdown in skin, the effects are small compared with that seen in tumors (84, 87), and no reductions in blood flow have been found in bladder and lung (84).

Chemotherapy. Numerous studies have also investigated the potential combination of VTAs with chemotherapeutic drugs. Those studies involving AIAs are summarized in Table 4 . Not listed in this table are those studies that combined AIAs with low-dose "metronomic" chemotherapy (160–163); the latter being a modified chemotherapeutic regime so that the chemotherapeutic drug itself has antiangiogenic properties, and as such, these studies represent the combination of AIAs rather than true combination of AIAs with chemotherapy. As can be seen in Table 4, the various permutations for combinations of AIAs with chemotherapeutic drugs are extensive. The schedules used are also highly variable, although typically these studies involved giving the AIAs and chemotherapeutic drugs over the same time period. What is clear is that the majority of studies reported an increased benefit of the combination approach, although in a few examples no additional benefit was found (164–166).


View this table:
[in this window]
[in a new window]

  		Table 4. Combination studies in tumors using AIAs and chemotherapeutic agents

 
Whether the increased effect of combining AIAs with drugs results in a response that is greater than additive is uncertain. However, there are reasons why a greater than additive response may be possible. These involve both nonpathophysiologic as well as pathophysiologic mediated effects. The combination of AIAs and chemotherapy can increase apoptosis. This has been seen in tumors in vivo (167–175) as well as with tumor and endothelial cells in vitro (72, 176, 177); this latter effect probably explains the decrease in MVD seen after such combination therapy (72, 165, 167, 172, 174, 178–180). A decrease in MVD might be expected to decrease drug delivery, and in fact, two studies have shown that treatment with TNP-470 can reduce the uptake of temozolomide in rat glioma models (181, 182). But such an effect would have a negative effect on the combination of AIAs and chemotherapeutic drugs, and this is clearly not seen with any of the studies listed in Table 4. Other pathophysiologic changes induced by AIAs, which could influence tumor response when AIAs and chemotherapy are combined, include tumor oxygenation and pH, both of which are critical factors in determining the activity of certain drugs (183–188). For example, bleomycin, cisplatin, 5-fluorouracil (5-FU), and methotrexate are more cytotoxic toward well-oxygenated cells in tumors (186, 188), although this dependency is not always seen in vitro (183, 184); bioreductive drugs are more effective under hypoxic conditions (183, 186, 187); and alkylating agents generally work better in hypoxia-related acidic conditions (185, 187). Changes in tumor pH following AIA treatment have not been reported, so the role this factor plays in the combination studies is unclear. Tumor oxygenation effects of AIAs have been investigated (Table 1), but the controversy surrounding the effects of AIAs on tumor oxygenation status makes it almost impossible to state whether this factor is responsible for the improved response observed when specific AIAs and drugs are combined. Nevertheless, in one study, the ability of thalidomide to enhance the antitumor effect of cyclophosphamide was shown to correlate with the maximal increase in tumor oxygenation by thalidomide (67). This was not the result of a decrease in hypoxia per se but rather correlated with the period of "normalization" of the tumor vasculature, and this resulted in an increased uptake of the cyclophosphamide into the tumor. Another pathophysiologic effect of AIAs that probably plays an important role is IFP. As previously mentioned, AIAs decrease IFP (46, 66, 71, 72), and it has been suggested that such a drop in IFP can result in an induced hydrostatic pressure gradient across tumor vasculature, which would enhance the tumor penetration of large molecules, thus resulting in an increase in drug uptake (71).

Whatever the explanation for the improvements in antitumor response when AIAs and chemotherapy drugs are combined, there is clear interest in developing clinical studies with such combinations (22). To date, the most convincing clinical study showing the potential benefit of combining AIAs and chemotherapy comes from the phase III trial combining the anti-VEGF monoclonal antibody bevacizumab with irinotecan, fluorouracil, and leucovorin (IFL) in previously untreated metastatic colorectal cancer (189). In that study, patients were randomized to receive IFL plus bevacizumab or IFL and placebo, and the results showed that the addition of bevacizumab to the chemotherapy regime significantly improved survival.

The combination of VDAs and chemotherapy has also been investigated, and these studies are summarized in Table 5 . For most of these combinations, the enhanced response is most likely attributable to the VDA and cytotoxic drugs targeting two distinct cell populations. By destroying the more central part of the tumor, VDA treatments eliminate cells in those areas that are less well vascularized and where the delivery of systemically administered chemotherapeutic drugs is limited. The cells in these areas are also oxygen deficient, are at low pH, and exhibit reduced proliferation, all of which can reduce the effectiveness of many chemotherapeutic drugs (183–188). Conversely, such drugs are more likely to kill cells in the viable rim of tumor tissue that survive the VDA treatment because of the better vascularization, improved oxygenation, pH, and proliferation status in those areas. However, this is not the situation with all combinations because the VDAs can improve the effectiveness of both bioreductive drugs, which are preferentially toxic to hypoxic cells (77, 83, 85, 190–193), and various drugs that show increased efficacy against cells at low pH (194, 195). In those situations, the enhanced response is probably due to these drugs killing those cells that are made hypoxic following the vascular shutdown induced by the VDA treatment yet had survived this insult. What is clear is that timing and sequencing of the VDAs and chemotherapeutic agents have major effects on the effectiveness of such combinations. Generally, the greatest enhancements are seen when the VDAs are administered within a few hours after giving the chemotherapeutic drug (83, 102, 153, 192, 195–198). Most studies show that at this time the enhancement is equivalent to a simple additive response, so it is unlikely that the vascular shutdown by the VDA traps the drug in the tumor. Indeed, in one study with CA4P and 5-FU, an enhanced tumor response was seen with the combination, yet pharmacokinetic analysis showed no effect of CA4P on tumor levels of 5-FU up to 4 hours after treatment, and at longer time intervals, there was actually an increase in drug clearance (197). However, a VDA-mediated increase in drug uptake in tumors has also been reported (199). In contrast, injecting VDAs immediately before chemotherapy often results in a loss of benefit (85, 153, 195), and this can probably be attributed to the reductions in blood flow by the VDA impairing the delivery of the chemotherapeutic drug to the tumor.


View this table:
[in this window]
[in a new window]

  		Table 5. Combination studies in tumors using VDAs and chemotherapeutic agents

 
Even if the combined VDA-chemotherapy treatment yields only an additive tumor response, such an outcome should still result in a therapeutic benefit because the pathophysiologic effects of VDAs that lead to the enhanced tumor response do not occur to the same extent in normal tissues (84, 87). Indeed, several preclinical studies have now shown improved antitumor effects without concomitant increases in either host toxicity (83, 153, 192, 195–198) or chemotherapy agent specific normal tissue damage (85, 198).

Other therapies. There are several other less conventional therapies with which VTAs have been combined and enhanced tumor response observed and in which the pathophysiologic effects of VTAs clearly play a significant role in the enhancement. A review of the pathophysiologic effects of VTAs and their implications for therapy would not be complete without some reference to these less conventional approaches. Principal among these is hyperthermia. The response of tumors to heat treatment is strongly dependent on tumor pathophysiology. Blood flow, being one of the major means by which heat is dissipated from tissues, will affect the ability to heat tumors. Generally, the lower the rate of blood flow, the easier it is to heat (200, 201). The tumor microenvironment also plays an important role in influencing the tumor response to heat. Several studies have shown that cells incubated under the oxygen-deprived and highly acidic adverse conditions, such as those often found in tumors (6, 7), are more sensitive to the cytotoxic action of heat (202, 203). This suggests that treatments that can modify tumor pathophysiology should be capable of changing heat sensitivity, and this has been shown using clamping (204, 205) or physiologic modifiers of blood flow (206–208).

Very few studies have investigated the potential of combining AIAs with hyperthermia. One study using the metalloproteinase inhibitor batimastat failed to show any enhancement of heat damage (209). An improved response to heat was observed with the synthetic analogue of fumagillin, TNP-470 (210, 211). However, because the effect was temperature dependent and the treatment schedule involved giving TNP-470 after heating, the enhancement was attributed to the AIA inhibiting angiogenesis that occurred following heat-induced vascular damage rather than due to any AIA-induced pathophysiologic changes (210, 211). Numerous studies have examined the combination of VDAs and heat. The VDAs include TNF (74, 75), ATO (80, 212), vinblastine (78), FAA (81, 124, 213), DMXAA (99), and CA4P (78, 214, 215). All resulted in an enhancement of the heat response. This outcome was time and schedule dependent, with the maximum response generally observed if the heat was started 1 to 6 hours after VDA administration (78, 80, 81, 99, 124, 212, 214, 215), corresponding to the maximal reduction in blood flow in those studies. As to the exact mechanism responsible for this enhancement, there is evidence for both an improved tumor heating (78, 124, 214) and a decrease in tumor pH (124–127).

On its own, hyperthermia has no role to play in the curative treatment of cancer and its clinical potential lies in its use as an adjuvant to other more conventional modalities, especially radiation (216). Indeed, several randomized clinical studies have shown the benefit of combining radiation and heat (217). Preclinical studies have now also shown that the effect of this thermoradiotherapy can be significantly improved by including FAA (32, 213), DMXAA (32, 218), or CA4P (32, 215) in the radiation and heat schedule. These VDAs were always administered after irradiating and before heating so as to exploit the pathophysiologic changes that could enhance both treatments.

Another "physical treatment" in which the tumor microenvironment influences response is PDT. PDT involves the administration of a photosensitizing agent and its subsequent activation by light, and this reaction is strongly dependent on oxygen concentration (219). Combining PDT with agents that have the potential to improve oxygen delivery is clearly a valid approach, and several studies have now shown that, when various tyrosine kinase inhibitors are combined with PDT, a significant improvement in tumor response can be obtained (220, 221). However, in those studies, the AIAs were always given after the PDT treatment, so the enhancement obtained was not the result of any pathophysiologic effect of the AIAs. Like hyperthermia, PDT not only kills tumor cells through a direct cytotoxic effect but can also have an indirect effect mediated through the induction of vascular damage (10, 23); thus, the results may have reflected an inhibition of angiogenesis following this vascular damage.

The pathophysiologic effects of VDAs have also been exploited to improve tumor response to radioimmunotherapy (222, 223) and both antibody-directed (ADEPT) and clostridia-directed (CDEPT) prodrug therapy (224, 225). The radioimmunotherapy studies have been done with DMXAA (222) and CA4P (223). Both VDAs were administered 48 hours after injecting the radioactive antibodies to allow sufficient time for maximal tumor accumulation of the latter before the VDA-induced inhibition of tumor blood flow occurred. With both VDAs, a substantial improved response was observed with the combination treatment. Although this may have simply been the result of independent actions of each treatment, the VDA killing hypoxic cells in the center of the tumor and the radioactive antibody killing cells in the more radiosensitive tumor rim, the results also suggested enhancement of the radioimmunotherapy response by entrapment of the radioactive antibody following VDA-induced vessel collapse (222, 223). Improved tumor response has also been observed for the combinations of ADEPT plus DMXAA (224) and CDEPT with DMXAA or ZD6126 (225). Timing and sequencing were important factors influencing response, and under optimal conditions, substantial VDA-induced entrapment of the ADEPT or CEDPT moieties was found (224, 225).


   Summary and Conclusions
Top
 Abstract
 Introduction
 Vascular-Targeting Approaches
 Pathophysiologic Effects of VTAs
 Combining VTAs with Other...
 Summary and Conclusions
References
 
Although VTAs on their own may elicit significant antitumor effects, their greatest use likely lies in their combination with more conventional therapies. However, the very nature of their mode of action will result in pathophysiologic changes that can influence these other therapies, in both a positive and a negative fashion, and thus, timing and sequencing become critical factors. When AIAs are combined with radiation, the opinion often expressed is that AIAs improve tumor oxygenation and that this can be exploited to enhance radiation response. But this is clearly too simple a generalization. AIAs can also decrease tumor oxygenation, and even under conditions where improvements in oxygenation are seen, only a narrow window of opportunity exists to exploit this effect. Clearly, unless it is possible to accurately and reliably predict the effects on tumor oxygenation for each AIA, each tumor type, and likely each individual tumor, then it would seem prudent to select a schedule that avoids any potentially negative consequences. For VDAs, the situation is clearer in that they induce hypoxia, and giving the VDA after irradiation would seem to be the optimal approach. With chemotherapy, VDAs should be administered in a fashion that minimizes the effects on blood flow to avoid affecting the delivery of the chemotherapeutic agent. Again, this would argue for giving the VDAs after the conventional anticancer drug. Indeed, shutting down blood flow after the chemotherapeutic agent has entered the tumor would still allow for other VDA-induced pathophysiologic changes to be exploited.

These findings suggest that spatial separation between the VTAs and other modalities offers the best strategy for maximizing antitumor effects while minimizing the possibility of reductions in the efficacy of the conventional therapy. Preclinical studies indicate that, when this is done, additive antitumor effects are usually observed. Such a response in the tumor can lead to a substantial therapeutic benefit, although further investigations of normal tissue side effects under these treatment conditions are needed. Overall, the pathophysiologic effects of VTAs need to be considered when the combination of VTAs with other cancer therapies is planned. Based on the results reported in a large body of preclinical investigations, significant improvements in treatment outcome in clinical studies combining VTAs and conventional anticancer therapies are anticipated.


   Acknowledgments
 
Grant support: Danish Cancer Society and the U.S. National Cancer Institute (USPHS grants CA 84408 and CA 89655).


   Footnotes
 
3 Ley, Horsman, and Kristjansen, unpublished observation. Back

4 Salmon and Siemann, unpublished observation. Back

Received 8/ 1/06. Accepted 11/ 6/06.


   References
Top
 Abstract
 Introduction
 Vascular-Targeting Approaches
 Pathophysiologic Effects of VTAs
 Combining VTAs with Other...
 Summary and Conclusions
 References
 

  1. Brem S, Brem H, Folkman J, Finkelstein D, Patz A. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 1976;36:2807–12.[Abstract/Free Full Text]
  2. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 1986;46:467–73.[Free Full Text]
  3. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dynamic theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999;59:4770–5.[Abstract/Free Full Text]
  4. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401–10.[CrossRef][Medline]
  5. Stoeltzing O, Ellis LM. The role of microvasculature in metastasis formation. In: Siemann DW, editor. Vascular-targeted therapies in oncology. Chichester: John Wiley & Sons, Ltd.; 2006. p.31–62.
  6. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic micro-environment of human tumors: a review. Cancer Res 1989;49:6449–65.[Abstract/Free Full Text]
  7. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198–206.[CrossRef][Medline]
  8. Coley Nauts H, Fowler GA, Bogatko FH. A review of the influence of bacterial infection and bacterial products (Coley's toxins) on malignant tumours in man. Acta Med Scand 1953;274:29–97.
  9. Woglem WH. A critique of tumour resistance. J Cancer Res 1923;7:283–311.
  10. Denekamp J, Hill S. Angiogenic attack as a therapeutic strategy for cancer. Radiother Oncol 1991;Suppl. 20:103–12.
  11. Denekamp J. The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eur J Clin Invest 1999;29:733–6.[CrossRef][Medline]
  12. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423–36.[CrossRef][Medline]
  13. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300:1155–9.[Abstract/Free Full Text]
  14. Wachsberger P, Burd R, Dicker AP. Tumor response to ionising radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms on interaction. Clin Cancer Res 2003;9:1957–71.[Abstract/Free Full Text]
  15. Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005;11:416–20.[Abstract/Free Full Text]
  16. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–76.[CrossRef][Medline]
  17. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677–84.[CrossRef][Medline]
  18. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727–39.[CrossRef][Medline]
  19. Marmé D. The impact of anti-angiogenic agents on cancer therapy. J Cancer Res Clin Oncol 2003;129:607–20.[CrossRef][Medline]
  20. Eskens FA. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 2004;90:1–7.[CrossRef][Medline]
  21. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967–74.[CrossRef][Medline]
  22. National Cancer Institute Web site: http://www.cancer.gov/clinicaltrials.
  23. Horsman MR, Overgaard J. Thermal radiosensitization in animal tumors: the potential for therapeutic gain. In: Urano M, Douple E, editors. Hyperthermia and oncology, vol. 2. Utrecht: VSP; 1985. p.113–45.
  24. Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999;80:57–64.
  25. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415–27.[Abstract/Free Full Text]
  26. Siemann DW, Chaplin DJ, Horsman MR. Vascular targeting therapies for treatment of malignant disease. Cancer 2004;100:2491–9.[CrossRef][Medline]
  27. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141–8.[CrossRef][Medline]
  28. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423–35.[CrossRef][Medline]
  29. Laird AD, Vajkoczy P, Shawver LK, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000;60:4152–60.[Abstract/Free Full Text]
  30. O'Reilly MS, Holmgren L, Chn C, Folkman J. Angiostatin induces and sustains dormancy of primary tumors in mice. Nat Med 1996;2:689–92.[CrossRef][Medline]
  31. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signalling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645–55.[Abstract/Free Full Text]
  32. Horsman MR, Murata R. Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys 2002;54:1518–23.[CrossRef][Medline]
  33. Landuyt W, Verdoes O, Darius DO, et al. Vascular targeting of solid tumours: a major "inverse" volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 2000;36:1833–43.[CrossRef][Medline]
  34. Siemann DW. Vascular targeting agents. Horizons Cancer Ther 2002;3:4–15.
  35. Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 2005;62:846–53.[CrossRef][Medline]
  36. Shi W, Siemann DW. Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo 2005;19:1045–50.[Medline]
  37. Ching LM, Xu ZF, Gummer BH, Palmer BD, Joseph WR, Baguley BC. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1995;72:339–43.[Medline]
  38. Ching LM, Browne WL, Tchernegovski R, Gregory T, Baguley BC, Palmer BD. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-{alpha} and enhancement of anti-tumour activity. Br J Cancer 1998;78:336–43.[Medline]
  39. Cao Z, Joseph WR, Browne WL, et al. Thalidomide increases both intra-tumoural tumour necrosis factor-{alpha} production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1999;80:716–23.[CrossRef][Medline]
  40. Mysliwski A, Bigda J, Koszalka P, Szmit E. Synergistic effect of the angiogenesis inhibitor TNP-470 and tumor necrosis factor (TNF) on Bomirski Ab melanoma in hamsters. Anticancer Res 2000;20:4643–7.[Medline]
  41. Landuyt W, Ahmed B, Nuyts S, et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 2001;49:443–50.[CrossRef][Medline]
  42. Nordsmark N, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31–9.[Medline]
  43. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113–7.[CrossRef][Medline]
  44. Hoeckel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509–15.[Abstract/Free Full Text]
  45. Nordsmark N, Alsner J, Keller J, et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001;84:1070–5.[CrossRef][Medline]
  46. Lee C-G, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565–70.[Abstract/Free Full Text]
  47. Gong H, Pöttgen C, Stüben G, Havers W, Stuschke M, Schweigerer L. Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: potentiation by irradiation. Int J Cancer 2003;106:723–8.[CrossRef][Medline]
  48. Drevs J, Müller-Driver R, Wittig C, et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002;62:4015–22.[Abstract/Free Full Text]
  49. Schuuring J, Bussink J, Bernsen HJJA, Peeters W, van der Kogel AJ. Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line. Int J Radiat Oncol Biol Phys 2005;61:529–34.[CrossRef][Medline]
  50. Hansen-Algenstaedt N, Stoll BR, Padera TP, et al. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2-blockade, hormone ablation, and chemotherapy. Cancer Res 2000;60:4556–60.[Abstract/Free Full Text]
  51. Shi W, Teschendorf C, Muzyczka N, Siemann DW. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother Oncol 2003;66:1–9.[CrossRef][Medline]
  52. Dings RPM, Williams BW, Song CW, Griffioen AW, Mayo KH, Griffin RJ. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer 2005;115:312–9.[CrossRef][Medline]
  53. Lund EL, Bastholm L, Kristjansen PEG. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 2000;6:971–8.[Abstract/Free Full Text]
  54. Hess C, Vuong V, Hegyi I, et al. Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 2001;85:2010–6.[CrossRef][Medline]
  55. Fenton BM, Paoni SF, Grimwood BG, Ding I. Disparate effects of endostatin on tumor vascular perfusion and hypoxia in two murine mammary carcinomas. Int J Radiat Oncol Biol Phys 2003;57:103